王旭，中國(guó)醫(yī)學(xué)科學(xué)院輸血研究所研究員、血漿蛋白質(zhì)研究中心課題組組長(zhǎng)、博士生導(dǎo)師，中國(guó)醫(yī)學(xué)科學(xué)院北京協(xié)和醫(yī)學(xué)院準(zhǔn)長(zhǎng)聘教職引進(jìn)人才。
王旭博士2015年畢業(yè)于北京協(xié)和醫(yī)學(xué)院，獲博士學(xué)位。2016-2021年先后在美國(guó)國(guó)家兒童醫(yī)學(xué)中心和馬里蘭大學(xué)醫(yī)學(xué)院從事博士后研究，2021-2023年在馬里蘭大學(xué)醫(yī)學(xué)院擔(dān)任副研究員，2024年加入中國(guó)醫(yī)學(xué)科學(xué)院輸血研究所，擔(dān)任研究員。長(zhǎng)期聚焦于天然免疫檢查點(diǎn)在炎癥性、代謝性疾病中的作用機(jī)制，靶向干預(yù)與臨床轉(zhuǎn)化，以第一/共一作者在Cell Metabolism，Science Translational Medicine，Signal Transduction and Targeted Therapy等雜志發(fā)表高水平論文。相關(guān)工作具有重要的臨床轉(zhuǎn)化價(jià)值和應(yīng)用前景，獲得FDA批準(zhǔn)臨床試驗(yàn)4項(xiàng)，申請(qǐng)國(guó)際專利4項(xiàng)，參與研發(fā)的CD24Fc項(xiàng)目以4.25億美元轉(zhuǎn)讓默沙東公司。
研究方向：
課題組致力于研究重大共性疾病的免疫調(diào)節(jié)機(jī)制與轉(zhuǎn)化應(yīng)用，包括：
1. 天然免疫應(yīng)答與炎癥性、代謝性疾??；
2. 心血管、血液系統(tǒng)穩(wěn)態(tài)及相關(guān)疾病的免疫調(diào)控機(jī)制與靶向干預(yù)；
3. 免疫穩(wěn)態(tài)失衡與重大疾病發(fā)生發(fā)展。
代表性論文：
1. Wang X#, Liu M#, Zhang J, Nicholas B., Zhang P, Zhang Y, Liu H, Wu W, Devenport M, Tao W, Yang M, Chen G, Chen Y, Zheng P and Liu Y. CD24-Siglec Axis Is an Innate Immune Checkpoint against Metaflammation and Metabolic Disorders. Cell Metabolism. 2022.
2. Liu M#, Wang X#, Du X#, Wu W, Zhang Y, Zhang P, Ai C, Devenport M, Su J, Musleh M, Su L, Liu Y, Zheng P. Soluble CTLA-4 Mutants Ameliorate Immune-Related Adverse Events but Preserve Therapeutic Efficacy by CTLA-4- and PD-1-Targeted Immunotherapy. Science Translational Medicine. 2023. (Co-first author)
3. Liu M#, Wang X#, Du X, Zhang Y, Ai C, Hu-Lieskovan S, Li T, Devenport M, Liu Y, Zheng P. CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. Signal Transduction and Targeted Therapy. 2022. (Co-first author)
4. Zhang R#, Wang X#, Qu J, Liu B, Zhang P, Zhang T, Fan P, Wang X, Xiao G, Su Y, Xie Y, Liu Y, Pei J, Zhang Z, Hao D, Xu P, Chen H, Liu D. Caloric Restriction Induces MicroRNAs to Improve Mitochondrial Proteostasis. iScience. 2019. (Co-first author)
5. Zhang S#, Wang X#, Zhang L, Yang X, Pan J, Ren G. Characterization of Monocyte Chemoattractant Proteins and CC Chemokine Receptor 2 Expression During Atherogenesis in Apolipoprotein E-null Mice. J Atheroscler Thromb. 2011. (Co-first author)
6. Flores R, Zhang P, Wu W, Wang X, Ye P, Zheng P, Liu Y. Siglec genes confer resistance to systemic lupus erythematosus in humans and mice. Cell Mol Immunol. 2019.
7. Muthana M, Du X, Liu M, Wang X, Wu W, Ai C, Su L, Zheng P, Liu Y. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. eLife. 2023.
8. Du X, Liu M, Su J, Flores R, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y, Zheng P. Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice. Cell Research. 2018.
9. Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski L, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, Zheng P, Liu Y. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Research. 2018.
10. Zhang Y, Qu Y, Lin Y, Wu X, Chen H, Wang X, Zhou K, Wei Y, Guo F, Yao C, He X, Liu L, Yang C, Guan Z, Wang S, Zhao J, Liu D, Zhao S, Xu W. Enoyl-CoA hydratase-1 regulates mTOR signaling and apoptosis by sensing nutrients. Nat Commun. 2017.
11. Liu Y, Wang T, Zhang R, Fu W, Wang X, Wang F, Gao P, Ding Y, Xie Y, Hao D, Chen H, Liu D. Calorie restriction protects against experimental abdominal aortic aneurysms in mice. J Exp Med. 2016.
聯(lián)系方式：
郵箱：wang_xu@pumc.edu.cn
